Loading...
•
Mar 31, 2023
Atea Q1 2023 Earnings Report
Atea Pharmaceuticals reported financial results for the first quarter ended March 31, 2023 and provided a business update.
Key Takeaways
Atea Pharmaceuticals reported first quarter results, highlighting the advancement of clinical trials and R&D efforts, including the continued enrollment in the Phase 3 SUNRISE-3 trial for COVID-19 and the upcoming Phase 2 trial for HCV treatment.
Phase 3 SUNRISE-3 trial for bemnifosbuvir in COVID-19 continues enrollment.
Phase 2 trial for bemnifosbuvir and ruzasvir combination in HCV on track for first patient dosed in Q2 2023.
Bemnifosbuvir granted Fast Track designation by the U.S. FDA.
Atea deprioritized its dengue program to focus on COVID-19 and HCV programs.